Tags: Cancer | liver | cancer | drug

FDA Declines to Approve Merck and Eisai's Liver Cancer Combo Therapy

FDA Declines to Approve Merck and Eisai's Liver Cancer Combo Therapy
(Stockbakery/Dreamstime.com)

Wednesday, 08 July 2020 07:11 AM

The U.S. Food and Drug Administration on Wednesday declined to approve a combination of Merck & Co Inc's blockbuster cancer drug Keytruda and Eisai Co Ltd's Lenvima for use in previously untreated patients with liver cancer.

The agency's complete response letter cited lack of sufficient evidence that the combination therapy had a meaningful advantage over available treatments for the condition, the companies said.

© 2020 Thomson/Reuters. All rights reserved.


   
1Like our page
2Share
Health-News
The U.S. Food and Drug Administration on Wednesday declined to approve a combination of Merck & Co Inc's blockbuster cancer drug Keytruda and Eisai Co Ltd's Lenvima for use in previously untreated patients with liver cancer.
liver, cancer, drug
64
2020-11-08
Wednesday, 08 July 2020 07:11 AM
Newsmax Media, Inc.
 
Newsmax TV Live

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved